Embodiments of the present invention generally relate to the treatment of a pelvic condition of a patient through the indirect stimulation of a pelvic neuromuscular structure of the patient.
Electrical stimulation systems have been used to deliver electrical stimulation therapy to patients to treat a variety of pelvic symptoms or pelvic conditions such as urinary incontinence. A typical electrical stimulation system includes one or more implantable medical leads coupled to an external or implantable electrical stimulator. The implantable medical lead may be percutaneously or surgically implanted in a patient on a temporary or permanent basis such that at least one stimulation electrode is positioned at a target stimulation site. The one or more electrodes may deliver electrical stimulation therapy to the target stimulation site in the form of electrical signals.
The target stimulation site of prior art pelvic condition treatment methods is generally directly related to the pelvic condition or symptom to be treated. For instance, prior art methods stimulate the sacral nerve at a location of S3 sacral foramen for the treatment of overactive bladder; the pudendal nerve at a location of Alcock's canal for the treatment of overactive bladder; a peri-urethral neuromuscular structure, such as Accessa® for the treatment of interstitial cystitis and overactive bladder; the internal urinary sphincter muscle for the treatment of urinary incontinence (see for example, U.S. Pat. Nos. 6,354,991, 6,652,449, 6,712,772 and 6,862,480); and the sacral nerve for the treatment of urinary retention.
Embodiments of the invention are generally directed to a method of treating of a pelvic condition of a patient through the indirect stimulation of a pelvic neuromuscular structure of the patient. In one embodiment of the method, an electrical stimulation signal is applied to a first neuromuscular structure of the patient. The electrical stimulation signal is communicated through a neural pathway to a second pelvic neuromuscular structure of the patient. The second neuromuscular structure is stimulated in response to the electrical stimulation signal communicated through the neural pathway. The pelvic condition is treated in response to the stimulation of the second pelvic neuromuscular structure.
This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not indented to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
Embodiments of the present invention generally relate to the treatment of a pelvic condition of a patient through the indirect stimulation of a pelvic neuromuscular structure of the patient. Before discussing various embodiments of the method, exemplary implantable electronic stimulator devices will be described with reference to
In one embodiment, the control unit 102 comprises circuitry for sensing electrical signals received by the electrodes 104, such as electromyography (EMG) signals, along with circuitry for processing the signals from the sensor 108. In one embodiment, the control unit 104 comprises circuitry for applying electrical stimulation waveforms to one or more of the electrodes 104. The electrical stimulation waveforms are designed to control and/or treat the desired condition of the pelvic region.
In one embodiment, the electrodes 104 are flexible intramuscular-type wire electrodes, approximately 1-35 millimeters long and 50-100 microns in diameter, in order to minimize patient discomfort. In one embodiment, the electrodes 104 comprise a spiral hook, as known in the art, so that they can be easily and permanently anchored in a pelvic muscle of a patient. The wire, from which the electrodes 104 are made, comprises a suitable conductive material, such as a biocompatible metal such as stainless steel, silver, a platinum/iridium alloy (90-10) or a nickel-chromium alloy. The leads 106 have a length that is suitable for the application, such as 5-10 centimeters long, and are surrounded by an insolating jacket 110 typically comprising silicone, polyurethane or and other flexible, biocompatible insolating material. An optional additional wire (not shown) inside the jacket 110 can serve as an antenna for the purpose of wireless communications with the device 100, in accordance with known methods.
In one embodiment, the control unit 102 comprises a circuitry for processing electrical signals received from the electrodes 104 or the sensor 108 and/or for applying an electrical waveform to one or both of the electrodes 104. In one embodiment, the circuitry is contained in a case 112 made of titanium or other suitable biocompatible metal. Typically, the case 112 is about 20 millimeters in diameter and 4 millimeters thick. For some applications, the case 112 serves as a ground electrode for the electrodes 104 when they are sensing or stimulating in a monopolar mode. Alternatively, the case 112 may comprise metal coated with a layer of biocompatible plastic, such as polymethyl methacrylate (PMMA) or silicon.
Although two electrodes 104A and 104B and one sensor 108 are shown attached to the control unit 102 in
One embodiment of the device 100 shown in
The electrode 104 can be anchored to a pelvic floor muscle of the patient by means of a fixation element 120, such as a helix, spiral hook or other anchor known in the art, as shown in the magnified schematic illustration of the distal end 116 of the lead 106 provided in
In one embodiment, the electrodes, generally referred to as 104, are approximately 3 millimeters in length, but can be much longer, such as less than about 80 millimeters in length, for example. The electrodes 104 are typically separated by approximately 3 millimeters along the length of the lead 106. In the same between the electrodes 104A and 104B a tip 124 of an EMG wire 126 may protrude approximately 100 microns through the casing 124, for those applications in which EMG sensing is desirable. Typically, the diameter of the wire 126 is approximately 50 microns, and the diameter of the casing 124 is approximately 1.5 millimeters.
As with the device 100 illustrated in
Embodiments of the invention are generally directed to a method of treating a pelvic condition of a patient through the indirect stimulation of a pelvic neuromuscular structure of the patient. The indirect stimulation of a pelvic neuromuscular structure is accomplished by taking advantage of the existence of cross reflex mechanisms or cross-talk between neural pathways of pelvic neuromuscular structures of the patient. As used herein, the term “neuromuscular structure” describes muscle tissue or nerves.
The general method of the present invention, in accordance with various embodiments of the invention, will be described with reference to the flowchart of
At step 138, the electrical stimulation signal or waveform 134, generated by the device 100 or other stimulator device, is applied to the first pelvic neuromuscular structure of the patient through the one or more electrodes 104. The electrical stimulation signal 136 is then communicated through a neural pathway 140 (e.g., afferent and/or efferent neural pathways) from the first pelvic neuromuscular structure 134 to a second pelvic neuromuscular structure 142 of the patient, as indicated at step 144. The location of the one or more electrodes 104 in or on the first pelvic neuromuscular structure 134 is displaced from the second pelvic neuromuscular structure by a distance D. The distance D can cross organs and their borders. In one embodiment, the distance D is greater than 1.0 cm. In accordance with another embodiment, the distance D is greater than approximately a few centimeters, such as 2-3.0 cm. In yet another embodiment, the distance D is 2-10 cm.
At step 146, the second pelvic neuromuscular structure is indirectly stimulated in response to the electrical stimulation signal communicated through the neural pathway 140. The condition or symptom of the patient is then treated, at least in part, in response to the stimulation signal 136 that is indirectly applied to the second pelvic neuromuscular structure 142 through the neural pathway 140, as indicated at step 148.
In accordance with exemplary embodiments, the first pelvic neuromuscular structure 134 of the patient comprises an anal neuromuscular structure and the second pelvic neuromuscular structure 142 of the patient comprises a urinary neuromuscular structure. Embodiments of the anal neuromuscular structure include an external anal sphincter muscle, an internal anal sphincter muscle and a pudendal nerve of the patient. The pudendal nerve, which innervates the external anal sphincter muscle and the external urinary sphincter muscle, forms at least a component of the neural pathway. In one embodiment, the anal neuromuscular structure containing the pudendal nerve is remote from the urinary neuromuscular structure that is being indirectly stimulated, by approximately the distance D.
Exemplary embodiments of the condition or symptom that may be treated by the direct application of the stimulation signal 136 to the first pelvic neuromuscular structure 134 and the indirect application of the stimulation signal 136 to the second pelvic neuromuscular structure 142 include urinary incontinence, urinary urgency and frequency, urinary retention, pelvic pain, endometriosis, fecal incontinence, constipation, sexual dysfunction, interstitial cystitis, chronic prostatitis and other pelvic conditions or symptoms.
Embodiments of the electrical stimulation signal or waveform 136 that is generated by the stimulator device 100 and applied to the first pelvic neuromuscular structure 134 through the one or more electrodes 104 may take on different forms depending on the particular application or pelvic condition being treated. For example, the electrical stimulation signal 136 may be monophasic or biphasic. In one embodiment, the electrical stimulation signal 136 comprises a plurality of electrical pulses. The electrical pulses may have a range of current and voltage amplitudes, duty cycles, frequencies (i.e., pulse repetition rates) and duration of application. It has been found that pulse frequencies in the range of 5 and 200 Hz are effective in engendering contraction in pelvic muscles, such as the levator ani muscle, but it may be desirable to use frequencies outside of this range. to In accordance with preferred embodiments, the electrical stimulation signal comprises a biphasic square wave having the following characteristics:
Current: 2-100 mA, preferably 2-4 mA;
Voltage: 1-15 V, preferably 1-3V;
Pulse width: 10 μs-2 ms, preferably 100-200 μs and variable in increments of 0.1 ms; and
Pulse repetition rate: 5-50 Hz, 50-1000 Hz, 12-25 Hz, preferably 10-30 Hz.
In one embodiment of the method, the application of the electrical stimulation signal 136 (step 138) is terminated after a predetermined period of time. In one embodiment, the predetermined period of time is 5-30 seconds. In another embodiment, the predetermined period of time is less than 6 hours. Other stimulation periods can be used depending on the particular application.
In one embodiment, the application of the electrical stimulation signal 136 is in response to the sensing of a physiological characteristic of the patient that is indicative of a pelvic condition requiring treatment. In one embodiment, the stimulator device 100 analyzes signals from the sensor 108 that are indicative of a physiological characteristic of the patient. The stimulator device 100 responsively applies the electrical stimulation signal 136 to the first pelvic neuromuscular structure 134 when the signal from the sensor 108 indicates the need to treat a pelvic condition, to which the signal relates. In one embodiment, the stimulator device 100 applies the electrical stimulation signal 136 to the first pelvic neuromuscular structure 134 when the signal from the sensor 108 indicates imminent urinary incontinence (e.g., urge and/or stress incontinence) or bladder retention problems.
In one embodiment, the pelvic condition of the patient that is to be treated through the application of the stimulation signal 136 to the anal neuromuscular structure (134) is urinary or bladder retention. Urinary retention occurs when the patient is unable to release urine from the bladder. This may be caused by either an outflow obstruction or poor bladder contractibility. In each case, the outflow resistance exceeds the pressure generated by contraction of the detrusor muscle that, under normal functioning, pushes the urine out of the bladder. In accordance with this embodiment, the urinary neuromuscular structure (142) of the patient comprises the detrusor muscle. The indirect stimulation of the detrusor muscle in response to the stimulation of the anal neuromuscular structure (134) contracts the detrusor muscle and, thus, increases the contractility of the bladder to treat the urinary or bladder retention condition of the patient.
Chart 1 below shows the pressures of the anal and bladder of the patient in response to the application of the electrical stimulation signal 136 (2 mA, 30 pulses/second, 100 μs pulse width duration) to the external anal sphincter (134) over the period of time identified by the thick solid line. The data illustrate the existence of a direct correlation between the stimulation of the external anal sphincter muscle (134) and the increase in contractility of the bladder. The increase in contractility of the bladder is presumably the result of the indirect stimulation of the detrusor muscle (142) by the electrical stimulation signal 136 communicated through the neural pathway 140 (pudendal nerve) from the external anal sphincter muscle 134.
Embodiments of the electrical stimulation signal for the treatment of urinary retention preferably comprise electrical pulses having a current amplitude of 2.0-4.0 mA, stimulation duration of 5-30 seconds, a pulse frequency of 10-30 Hz and a pulse duration of 100-200 μsec. In one embodiment, the electrical stimulation signal has a current amplitude of 2 mA, a stimulation duration of 10 seconds, a pulse frequency of 30 Hz and pulse duration of 100 μsec.
In accordance with another embodiment, the pelvic condition of the patient that is to be treated through the application of the stimulation signal 136 to the anal neuromuscular structure (134) is urinary incontinence. Urinary incontinence is the inability of the patient to control the release of urine from his or her bladder. Embodiments of the invention include the treatment of various types of urinary incontinence including stress incontinence, urge incontinence and mixed incontinence. In each case, the pressure on the bladder exceeds the outflow resistance produced by the internal and/or external urinary sphincter muscles resulting in involuntary urination.
In accordance with this embodiment, the urinary neuromuscular structure (142) of the patient comprises the internal urinary sphincter muscle and/or the external urinary sphincter muscle. The electrical stimulation signal 136 that is applied to the anal neuromuscular structure (134) in step 132 is communicated to the internal and/or external urinary sphincter muscle (142) at least partially through the pelvic, hypogastric and/or pudendal nerve (i.e., neural pathway 140). In response to this indirect application of the electrical stimulation signal 136 to the internal and/or external urinary sphincter muscles (142), the internal and/or external urinary sphincter muscles (142) contract and restrict the flow of urine through the urethra of the patient thereby treating the urinary incontinence condition.
Embodiments of the electrical stimulation signal 136 for the treatment of urinary incontinence preferably comprise electrical pulses having a current amplitude of 3.0-4.0 mA, a voltage amplitude of 1-3 V, a stimulation duration that is intermittent or continuous over a period of several seconds to several hours (e.g., 6 hours), a pulse frequency of 12-25 Hz and a pulse duration of 10-200 μsec. In one embodiment, the electrical stimulation signal has a current amplitude of 3 mA, a voltage amplitude of 3 V, a pulse frequency of 25 Hz and pulse duration of 200 μsec.
One advantage of the method of the present invention is the ability to place the electrode lead(s) 104 of the stimulator device 100 at a location of the patient that is, for example, easier to access (i.e., less intrusive), more comfortable for the patient, easier to monitor, easier to maintain, etc. For example, it is far less intrusive to the patient to implant an electrode in the external anal sphincter muscle to treat, for example, urinary incontinence or bladder retention, than it is to implant an electrode in the internal urinary sphincter muscle or the detrusor muscle of the patient.
In one embodiment, the first pelvic neuromuscular structure 134 of the patient comprises a urinary neuromuscular structure of the patient, embodiments of which are described above, and the second pelvic neuromuscular structure 142 of the patient comprises an anal neuromuscular structure of the patient, embodiments of which are described above. In accordance with this embodiment, stimulation signals are indirectly applied to the anal neuromuscular structure through the stimulation of the urinary pelvic neuromuscular structure using the neural pathway (e.g., pudendal nerve branches). Exemplary conditions or symptoms that may be treated using this method include fecal incontinence, constipation, endometriosis-induced dysmenorrhea, erectile dysfunction, irritable bowel syndrome, vulvodynia. and other pelvic conditions or symptoms.
Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention. For example, the embodiments of the electrical stimulation signal described above are exemplary and other electrical stimulation signals may be used in order to provide the desired treatment of a pelvic condition of a patient.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US10/24287 | 2/16/2010 | WO | 00 | 8/16/2011 |
Number | Date | Country | |
---|---|---|---|
61153362 | Feb 2009 | US |